Role of Antioxidant and Anti-inflammatory Parameters in the Renoprotective Effects of Valsartan against Renal Ischemia-Reperfusion Injury in Male Rats

Document Type : Original Article

Authors

1 Department of Animal Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran

2 Department of Physiology, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran

3 Department of Pharmacology, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran

10.30476/tips.2025.108768.1322

Abstract

ABSTRACT
Renal ischemia-reperfusion (I/R) injury, causing acute kidney failure, involves inflammation, oxidative stress, and dysfunction. Valsartan, an angiotensin II receptor blocker, lowers blood pressure and has anti-inflammatory and antioxidant effects. We examined its renoprotective effects via antioxidant and anti-inflammatory parameters in a male rat I/R model. In this study, 18 male Wistar rats (250–300 g) were divided into sham control, I/R control, and I/R treated with valsartan groups. Valsartan (60 mg/kg) was gavaged for one week before and immediately after I/R. After 24 hours, urine, blood, and kidney tissue samples were collected. Finally, biochemical and functional kidney indices, mean blood pressure, inflammatory and oxidative stress markers, and histological findings were assessed. In the I/R group, blood urea nitrogen (BUN), tumor necrosis factor-alpha (TNF-α), tissue malondialdehyde (MDA), fractional excretion of sodium (FENa), fractional excretion of potassium (FEK), urinary Na, and plasma Cr increased significantly, while glomerular filtration rate (GFR), tissue ferric reducing antioxidant power (FRAP), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and mean arterial pressure (MAP) decreased (P<0.05). Valsartan significantly reduced urinary urea, BUN, TNF-α, and FENa, improved antioxidant enzymes, plasma FRAP, and increased urinary Cr, K, and Na compared to I/R group (P<0.05). In this group absolute potassium excretion (UKV0) increased, FENa and MAP decreased (both P<0.05) but plasma Cr not affected. Histopathology showed reduced renal injury. Valsartan protects against I/R-induced injuries by reducing inflammation, boosting antioxidant activity, improving renal function, and lessening tissue damage. Further studies are needed to confirm its potential in managing these injuries.

Keywords